@article{5a340b0df57c48fda04efbba9cc184bd,
title = "Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic",
abstract = "The emergence of novel coronavirus 2019 (COVID-19)1 and the subsequent pandemic present a unique challenge to neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD).",
author = "Wallace Brownlee and Dennis Bourdette and Simon Broadley and Joep Killestein and Olga Ciccarelli",
note = "Funding Information: W. Brownlee has accepted speaker honoraria and/or participated in advisory boards for Biogen, Merck, Mylan, Novartis, Roche, and Sanofi Genzyme. D. Bourdette has received consultation fees from Magellan Health and has research grants from the National MS Society. S. Broadley has accepted speaker and/or advisory board honoraria and travel sponsorship from Bayer Schering, Biogen Idec, Merck, Novartis, and Sanofi Genzyme; has been an investigator in clinical trials sponsored by Biogen Idec, Novartis, and Genzyme; and was the recipient of an unencumbered research grant from Biogen Idec. J. Killestein has accepted speaker and consulting fees from Merck, Biogen, Teva, Sanofi, Genzyme, Roche, and Novartis. O. Ciccarelli has acted as a consultant for Roche, Novartis, and Merck in the last 12 months. She is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC), London, United Kingdom. She is the Deputy Editor of Neurology. Go to Neurology.org/N for full disclosures. Publisher Copyright: {\textcopyright} American Academy of Neurology.",
year = "2020",
month = jun,
day = "2",
doi = "10.1212/WNL.0000000000009507",
language = "English (US)",
volume = "94",
pages = "949--952",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "22",
}